A study in Technology & Innovation that reviewed use of PET with amyloid imaging agent Pittsburgh compound B found that patients with Alzheimer's disease had prominent PiB retention in the cortical areas of the brain and lower retention in white matter, mirroring findings in post-mortem studies. The results suggest the importance of amyloid imaging for assessing AD risk and prognosis, but challenges persist, such as determining how to detect the earliest amyloid accumulation and understanding how that early buildup relates to cognitive decline in the future, researcher Ann Cohen said.
Quantitative Analysis for Amyloid PET The IDEAS trial has led to increased use of Amyloid PET. Because visual interpretation of Amyloid PET alone can be difficult and subjective, MIMneuro® provides an automated quantification analysis solution that highlights significantly increased uptake of amyloid PET tracers. Learn more...
A study of 178 patients with advanced cancer found only 5% had enough knowledge about their illness to make informed medical decisions, researchers reported in the Journal of Clinical Oncology, although those who had recently had end-of-life conversations with a doctor had a better understanding of their prognosis. The patients were studied before and after they had medical scans and discussions about the tests with their physicians, and data showed that prior to the scans, only nine knew they were in the late stages of an incurable cancer.
A study found the Modified Frailty Index was a strong predictor of ICU-level complications, unplanned reoperations and overall morbidity for patients having head and neck cancer surgeries. The study in JAMA Otolaryngology -- Head & Neck Surgery found the tool did not predict unplanned readmission or mortality.
PDI Therapeutics, a cancer immunotherapy developer, has been established by Avalon Ventures under an expanded build-to-buy collaboration with GlaxoSmithKline. PDI is entitled to receive Series A financing from Avalon and research and development support from GSK valued at a total of $10 million. The company is the eighth firm launched through Avalon's and GSK's alliance.
The UK's National Institute for Health and Care Excellence will not recommend the use of Roche's HER2-positive breast cancer therapy Perjeta, or pertuzumab, citing a lack of evidence of long-term benefits.
A survey of 1,511 adults found more than 90% were satisfied with their primary care physician, but 62% said they were worried about their ability to pay for medical care if they became sick or were injured. The Harris poll commissioned by the Physicians Foundation found 28% of respondents said they had skipped a test or follow-up appointment or did not seek care for a medical issue due to cost concerns.
Roche argued at the Delhi High Court that approving a biosimilar version of its cancer drug Avastin, or bevacizumab, from Hetero Drugs would be a misuse of proprietary data and could harm the company's reputation. Roche is challenging the recommendation process used by a panel of the Drugs Controller General of India.
A bill in the Michigan House of Representatives would provide equivalent insurance coverage for intravenous and oral cancer drugs. Oral drugs typically have higher out-of-pocket costs for patients. A similar measure was passed in the Michigan Senate this month.
Current provider-facing telehealth programs will soon be replaced with mHealth tools that are more patient-focused, according to Avizia and Modern Healthcare's survey of almost 280 health care executives. Survey respondents identified computer workstations, telemedicine carts and "specialized telemedicine peripherals" as the most popular telemedicine devices they use. They said they anticipate using video visits through the EMR, consumer-facing apps, company-owned and personal mobile devices, FDA-approved biometric patient monitoring devices and consumer-grade monitoring devices in the future.
On May 2, SNMMI's Clinical Trials Network co-sponsored a workshop with the National Cancer Institute titled "Immune Modulation Therapy and Imaging: What can we do in clinical trials now?" The goal of the conference was to identify "shovel-ready" projects that could be added to clinical trials, either NCI- or industry-sponsored, by the end of 2016. The full video webcast is available for viewing.
The ARRT-SNMMI Technologist Section Professional Development Grants serve to support nuclear medicine technologists wishing to pursue additional educational opportunities to advance their professional career. Additional education opportunities include, but are not limited to: continuing education courses (live or online), ARRT certification exams (application fees), degree seeking education (associate, bachelor's or master's), etc. Thirteen grants will be awarded, for $500 each. Deadline: Aug. 1. Learn more.
If you're not reaching back to help anyone, then you're not building a legacy.
Germany Kent, media personality
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at firstname.lastname@example.org.